Plain-English translation of NCT07304284 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new cholera vaccine called Biovac OCV-S to see if it protects people against cholera as well as an existing cholera vaccine (Euvichol®-Plus). Researchers will also check whether the medication is safe and whether different batches of it work consistently. The trial will include healthy children and adults, as well as adults living with HIV who are on stable treatment.
Cholera is a serious disease that affects millions of people worldwide, especially in areas with limited access to clean water. This trial exists to develop and confirm that this new medication can safely protect people from cholera, giving more options for vaccination in regions that need it most.
You likely qualify if…
You likely don't qualify if…
You will receive two doses of the study medication by mouth, spaced 2 weeks apart. Throughout the study, you will visit the clinic several times over about 27 weeks so researchers can check your health, take blood samples to see if your body is protected against cholera, and monitor for any side effects. The visits and safety checks help researchers understand whether the medication works well and is safe for different age groups.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
South Africa